Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms

Therapeutic Drug Monitoring

Volumn 26, Issue 5, 2004, Pages 534-540

  Hung, Chin Chuan ^a   Lin, Chun Jung ^a   Chen, Chih Chuan ^b   Chang, Chee Jen ^b   Liou, Horng Huei ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

NONMEM; Pharmacogenetics; Phenytoin

Indexed keywords

ALBUMIN; CARBAMAZEPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; ENZYME ACTIVITY; EPILEPSY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICHAELIS CONSTANT; OPTIMAL DRUG DOSE; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; GENOTYPE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIXED FUNCTION OXYGENASES; PHENYTOIN; POLYMORPHISM, GENETIC; TAIWAN;

EID: 4744365530     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200410000-00012     Document Type: Article

References (20)

1. Bajpai M, Roskos LK, Shen DD, et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos. 1996;24:1401-1403.
2. de Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419-15422.
3. de Morais SMF, Goldstein JA, Xie HG, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther. 1995;58:404-411.
4. Wang S-L, Huang J-D, Lai M-D, et al. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 1995;5:37-42.
5. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP 2C9-Leu359 allelic variant in the tobutamide polymorphism. Pharmacogenetics. 1996;6:341-349.
6. Wilkinson GR. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, Goodman Gilman A, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed. New York, McGraw-Hill, 2002.
7. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics. 1997;7:405-409.
8. Yoon YR, Shon JH, Kim MK, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol. 2001;51:277-280.
9. Scordo MG, Aklillu E, Yasar U, et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and black African population. Br J Clin Pharmacol. 2001;52:447-450.
10. Fritz S, Lindner W, Roots I, et al. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther. 1987;241:615-622.
11. Edeki TI, Brase DA. Phenytoin disposition and toxicity: Role of pharmacogenetic and interethnic factors. Drug Metab Rev. 1995;27:449-469.
12. Odani A, Hashimoto Y, Otsuki Y, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther. 1997;62:287-292.
13. Mamiya K, Ieiri I, Shimamoto J, et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia. 1998;39:1317-1323.
14. Wang SL, Huang JD, Lai MD, et al. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 1995;5:37-42.
15. de Morais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594-598.
16. Beal SL, Sheiner LB, eds. NONMEM User's Guide. San Francisco: NONMEM Project Group, University of California, 1994.
17. Caplan YH, Levine B. Application of the Abbott TDx lidocaine, phenytoin, and phenobarbital assays to postmortem blood specimens. J Anal Toxicol. 1988;12:265-267.
18. Suzuki Y, Mimaki T, Cox S, et al. Phenytoin age-dose-concentration relationship in children. Ther Drug Monit. 1994;16:145-150.
19. Stubbins MJ, Harries LW, Smith G, et al. Genetic analysis of the human cytochrome P450 CYP 2C9 locus. Pharmacogenetics. 1996;6:429-439.
20. Rettie AE, Haining RL, Bajpai M, et al. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 1999;35:253-255.